| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:HDAC6-IN-5
CAS:2413603-15-1
Package:25mg/RMB 10600;100mg/RMB 17500;50mg/RMB 13800
|
Benzamide, 4-[(2-bromo-9-acridinyl)amino]-N-hydroxy- manufacturers
- HDAC6-IN-5
-
- $1520.00 / 25mg
-
2025-04-30
- CAS:2413603-15-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Benzamide, 4-[(2-bromo-9-acridinyl)amino]-N-hydroxy- Basic information |
| | Benzamide, 4-[(2-bromo-9-acridinyl)amino]-N-hydroxy- Chemical Properties |
| density | 1.604±0.06 g/cm3(Predicted) | | pka | 9.01±0.10(Predicted) |
| | Benzamide, 4-[(2-bromo-9-acridinyl)amino]-N-hydroxy- Usage And Synthesis |
| Uses | HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM. HDAC6-IN-5 exhibits strong inhibitory activity against Aβ1-42 self-aggregation and AChE, with IC50 values of 3.0 and 0.72 μM. HDAC6-IN-5 can enhance neurite outgrowth without significant neurotoxicity[1]. | | IC 50 | AChE: 0.72 μM (IC50); HDAC6: 0.026 ± 0. μM (IC50); HDAC1: 0.09 ± 0.0 μM (IC50); HDAC: 0.16 ± 0.0 μM (IC50); HDAC3: 0.33 ± 0. μM (IC50); HDAC2: 0.48 ± 0.0 μM (IC50); HDAC9: 5.51 ± 0.0 μM (IC50); HDAC5: 7.19 ± 0.4 μM (IC50); HDAC4: 7.85 ± 0.6 μM (IC50); HDAC7: 9.13 ± 0.3 μM (IC50) | | References | [1] Tseng HJ, et al. Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease. Eur J Med Chem. 2020 Apr 15;192:112193. DOI:10.1016/j.ejmech.2020.112193 |
| | Benzamide, 4-[(2-bromo-9-acridinyl)amino]-N-hydroxy- Preparation Products And Raw materials |
|